| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Alena Gros | Q38801343 | ||
| P2093 | author name string | Paul F Robbins | |
| John R Wunderlich | |||
| Simon Turcotte | |||
| Eric Tran | |||
| Chyi-Chia R Lee | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Cancer genome landscapes | Q22242276 | ||
| Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor | Q24312048 | ||
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 | ||
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients | Q24598792 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Analysis of the processing of seven human tumor antigens by intermediate proteasomes. | Q39290186 | ||
| A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. | Q39621147 | ||
| Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications | Q43066428 | ||
| Epitope landscape in breast and colorectal cancer. | Q51894674 | ||
| Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Q56899396 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Tumor-specific cytolysis by lymphocytes infiltrating human melanomas | Q69738303 | ||
| Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion | Q70535234 | ||
| CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy | Q81737517 | ||
| IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis | Q24646236 | ||
| Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes | Q24647904 | ||
| Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes | Q24649346 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Cancer/testis antigens, gametogenesis and cancer | Q29616129 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| The immune contexture in human tumours: impact on clinical outcome | Q29620667 | ||
| Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells | Q30621114 | ||
| Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer | Q33389767 | ||
| Use of reprogrammed cells to identify therapy for respiratory papillomatosis | Q33648479 | ||
| Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients | Q34111120 | ||
| ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells | Q34242167 | ||
| Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma | Q34300883 | ||
| T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. | Q34621730 | ||
| Expression of tumour-specific antigens underlies cancer immunoediting | Q35785378 | ||
| Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities | Q35850673 | ||
| Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability | Q36286127 | ||
| Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells | Q36326582 | ||
| Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes | Q36327157 | ||
| Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma | Q36442539 | ||
| Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients | Q36444798 | ||
| Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients | Q36551911 | ||
| MHC class I antigens and immune surveillance in transformed cells. | Q36714774 | ||
| Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. | Q37065838 | ||
| Tumour immunity: effector response to tumour and role of the microenvironment | Q37085136 | ||
| Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy | Q37107516 | ||
| Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting | Q37418530 | ||
| The three main stumbling blocks for anticancer T cells | Q37996703 | ||
| Translational applications of flow cytometry in clinical practice. | Q38007401 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 331-343 | |
| P577 | publication date | 2013-11-11 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy | |
| P478 | volume | 20 |
| Q54139665 | 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. |
| Q36943923 | A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells |
| Q41963078 | Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy |
| Q93337436 | Adoptive cellular therapies: the current landscape |
| Q90468357 | B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies |
| Q57075029 | CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer |
| Q55715408 | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. |
| Q91782530 | Determinants for Neoantigen Identification |
| Q37346107 | Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors |
| Q49461096 | Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer |
| Q38923514 | Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer. |
| Q35981245 | Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy |
| Q37012537 | Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. |
| Q37697218 | Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. |
| Q41110505 | Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. |
| Q26781038 | Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations |
| Q26740208 | Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer |
| Q38797183 | Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. |
| Q92824998 | Novel Biomarkers for Personalized Cancer Immunotherapy |
| Q55394623 | PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. |
| Q94503515 | Prognostic value of CD73 expression in resected colorectal cancer liver metastasis |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q98178302 | The High Level of Tertiary Lymphoid Structure Is Correlated With Superior Survival in Patients With Advanced Gastric Cancer |
| Q39123136 | Tumor regulation of the tissue environment in the liver |
| Q38636573 | Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. |
| Q91341197 | Tumour-reactive T cell subsets in the microenvironment of ovarian cancer |
| Q42376660 | Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry |
| Q92523541 | Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers |
Search more.